- 01Your own LL-37 vs LL-37 from a vial
The LL-37 your neutrophils and skin release, at the right place and moment, is well studied. LL-37 bought in a vial has been tested for benefit in people only as a wound solution on leg ulcers, and the larger trial found no overall effect, so the body's biology is no evidence that taking it works.
The most useful fact to know before looking at a vial of LL-37 is that your body already makes it, and that its output depends partly on vitamin D, a number an ordinary blood test reports. The biology of the body's own LL-37 is well mapped. The evidence for taking extra LL-37 is close to empty.
LL-37 at a glance
| Question | Answer |
|---|---|
| What it is | A host-defence (germ-fighting) peptide; the active fragment of human cathelicidin |
| Made by | Neutrophils, skin cells, airway lining, gut lining |
| Switched on by | Infection, wounds, active vitamin D 1 |
| FDA status (Nov 2026) | Not approved; not eligible for compounding; advisory committee review due by end of February 2027 8 |
| Best human evidence | Topical solution on venous leg ulcers: one positive small trial, one negative larger trial |
| Main risks | Damage to human cells at high levels, immune reactions, impurities, flares of autoimmune and skin disease, unknown cancer effects |
What is LL-37 peptide?
The name describes the molecule. LL-37 is a chain of 37 amino acids, and the first two are leucines (L in the amino acid alphabet). Cells make it as part of a larger precursor protein, hCAP18 (human cationic antimicrobial protein, 18 kilodaltons), which the CAMP gene encodes. hCAP18 is the only cathelicidin humans have. Cathelicidin is the name of the precursor family; LL-37 is the active piece cut from it, so the two words are often used for the same thing, though they are different molecules.
Neutrophils, the most common white blood cells, keep the largest store. They hold hCAP18 inside granules, small packets in the cell, and when a neutrophil releases those granules at an infection, an enzyme called proteinase 3 cuts hCAP18 to free LL-37 (Sørensen and colleagues, Blood, 2001). Skin cells, the lining of the airways and the gut lining make their own LL-37 when injured or infected.
What does LL-37 do in the body?
- Punches holes in the membranes of bacteria, fungi and some viruses.
- Breaks up biofilms, the slimy mats bacteria build to shelter from antibiotics.
- Binds and neutralises LPS (lipopolysaccharide), the bacterial wall fragment that sets off fever and inflammation.
- Calls in other immune cells and adjusts how strongly they react.
- Helps wounds close and helps grow new blood vessels.
There is a catch in that list. At the salt and blood-protein levels inside the body, LL-37's direct killing power drops sharply, so Bowdish and colleagues argued in 2005 that its main day-to-day job is immune signalling. Two findings show the peptide matters. In preclinical knockout studies, losing the equivalent cathelicidin led to worse group A strep skin infections (Nizet and colleagues, Nature, 2001). People with Kostmann disease, a severe inherited lack of neutrophils, have no LL-37 in their neutrophils or saliva and develop severe gum disease (Pütsep and colleagues, Lancet, 2002).
LL-37 and vitamin D: the lever you can test
The strongest human link to LL-37 runs through vitamin D. In 2005 Gombart, Borregaard and Koeffler showed that active vitamin D binds the vitamin D receptor, which sits directly on the CAMP gene and switches it on in immune cells 1.
Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor.Gombart, Borregaard and Koeffler, title of their 2005 paper in the FASEB Journal
A year later, Liu and colleagues showed the system working in human macrophages (immune cells that swallow germs): an infection signal makes the macrophage convert stored vitamin D into its active form, which turns on cathelicidin and helps kill tuberculosis bacteria. Serum low in 25-hydroxyvitamin D (25-OH D, the storage form a blood test measures) produced a weaker cathelicidin response 2.
How your vitamin D level becomes LL-37 at an infection
Two human results follow from that mechanism. In people with eczema, oral vitamin D3 for three weeks raised cathelicidin in the skin lesions (Hata and colleagues, Journal of Allergy and Clinical Immunology, 2008). And a 2017 BMJ analysis of individual data from 25 trials found that vitamin D supplements modestly lowered the odds of acute respiratory infection, with the clearest benefit in people who started below 25 nmol/L, about 10 ng/mL 3. The vitamin D unit converter turns one unit into the other.
Markers to read beside LL-37
The one part of this system a routine blood test can see is 25-OH D. A low result points to vitamin D deficiency, a common, testable problem that a clinician can confirm and treat, and that is a better-studied place to start than an injectable peptide.
The supplement with evidence on this pathway
LL-37 peptide benefits: what the research shows
Sellers list a long set of benefits. Sorted by the best evidence behind each claim, most of the list rests on lab dishes and preclinical work.
| Claimed benefit | Best evidence | Tested in people? | Verdict |
|---|---|---|---|
| Kills bacteria, including resistant strains | Lab studies | No | Unproven as a treatment |
| Heals wounds | Two topical trials in venous leg ulcers (34 and 148 patients) | Yes, on the skin only | Mixed; the larger trial was negative overall 4 |
| Injected immune support | None | No | No human data |
| Clears Lyme disease or biofilms | Lab and preclinical | No | Unproven |
| Fixes SIBO or leaky gut | Preclinical | No | Unproven |
| Better infection defence via vitamin D | Gene and cell studies; vitamin D trials | Vitamin D, yes; LL-37 itself, no | Modest benefit for vitamin D, mainly when deficient 3 |
The wound trials are the only real human efficacy data. In 2014, Grönberg and colleagues gave 34 people with hard-to-heal venous leg ulcers an LL-37 solution or placebo on the wound, and the LL-37 groups healed faster (Wound Repair and Regeneration, 2014). The follow-up phase IIb trial in 148 patients found no significant improvement in healing overall. Only a post hoc analysis (a look at subgroups chosen after the results were in) suggested a benefit in wounds of 10 cm² or larger 4. A post hoc signal is a reason for another trial, and no such trial has reported.
The distinction that matters on this page is between the LL-37 your neutrophils release, at a precise spot and moment, and LL-37 from a vial. The body's version is well studied. A bought version arrives at a dose, route, purity and timing that no human trial has tested, so the body's biology cannot stand in as evidence that taking it works.
The catch: when LL-37 fuels disease
In psoriasis, LL-37 binds fragments of the body's own DNA, and the pair switches on plasmacytoid dendritic cells, immune cells that release interferon and drive the plaques 5. Lande and colleagues later found that many people with psoriasis carry T cells that attack LL-37 itself, which makes it an autoantigen, a self-protein the immune system targets (Nature Communications, 2014).
In rosacea, skin carries abnormally high cathelicidin, cut into unusual forms by an overactive enzyme, and in preclinical tests those fragments produced rosacea-like redness and inflammation 6. In lupus, neutrophils throw out nets of DNA studded with LL-37 that feed the same interferon loop. Cancer cuts both ways: LL-37 helped ovarian tumours recruit supporting cells (Coffelt and colleagues, PNAS, 2009) and was linked to more invasive behaviour in breast cancer cells (Weber and colleagues, Breast Cancer Research, 2009), while in some gut cancers it appears to slow growth. Eczema sits at the other end, with less LL-37 in the skin than psoriasis, which may help explain why eczema skin gets infected more often (Ong and colleagues, New England Journal of Medicine, 2002).
Side effects and risks of taking LL-37
- Cell damage: LL-37 attacks membranes without fully telling microbes from human cells, so it harms human cells at higher concentrations (Oren and colleagues, Biochemical Journal, 1999).
- Immune reactions: FDA's review flagged immunogenicity (the body forming antibodies or allergic reactions to the peptide) and peptide-related impurities, and said it lacks the human safety data to know whether LL-37 causes harm 7.
- No quality control: vials labelled 'research use only' are not made or checked to drug standards, so the contents, dose and sterility are unknown.
- Flares: given its role in psoriasis, rosacea and lupus, extra LL-37 could plausibly set off skin or autoimmune flares; no trial has measured this.
- Cancer and fertility: FDA noted preclinical findings that LL-37 can promote tumours in some tissues and may harm male reproduction; the long-term effect in people is unknown 7.
Who should avoid LL-37
The specific risks fall on people with psoriasis, rosacea, lupus or rheumatoid arthritis, anyone with a current or past cancer, and anyone pregnant or breastfeeding, where there are no safety data at all. Anyone in those groups who is weighing LL-37 should talk it through with the clinician who manages that condition.
Is LL-37 FDA-approved, and is it legal?
No LL-37 product is approved anywhere as a medicine. In the US, the open question is compounding, where a pharmacy mixes a drug for one patient under section 503A of federal drug law. Here is where LL-37 stands.
- 12023: Category 2FDA placed cathelicidin LL-37 on its list of bulk substances that may present significant safety risks, citing immunogenicity, peptide impurities and too little human safety data 7 8.
- 2April 2026: off Category 2, sent for reviewFDA's list now shows LL-37 among peptides moved out of Category 2 after their nominations were withdrawn, and FDA asked its advisory committee to consider adding 12 peptides, LL-37 among them, to the list pharmacies may compound from 7 8.
- 3Still not compoundableLeaving Category 2 does not by itself make LL-37 eligible for compounding; it still needs a place on the 503A bulks list 8.
- 4By end of February 2027: advisory committeeFDA's Pharmacy Compounding Advisory Committee is due to discuss LL-37. Its vote advises FDA and does not bind it 8.
Websites selling LL-37 as a research chemical are not a legal source of a medicine for people. For tested athletes, the World Anti-Doping Agency's S0 class bans any substance without approval for human therapeutic use, and LL-37 has no such approval.
What dose of LL-37 do people use?
No human dose of LL-37 has been established for injection or nasal use, because no trial has tested those routes for benefit. The only controlled human dosing was a solution applied to leg ulcers inside the two wound trials 4. LifeFrom does not publish protocols. A clinician who knows your history, and your 25-OH D result, is the person to ask.
Can a blood test measure LL-37?
No routine lab test measures LL-37; the ELISA kits that detect it are research tools. A standard panel shows the parts of the system around it: 25-OH D for the vitamin D supply, a white blood cell count and absolute neutrophils for the cells that store LL-37 (the absolute neutrophil count calculator works it out from a CBC), and hs-CRP for background inflammation. Our guide to inflammation markers explains how those read together, and a result outside its range is one to take to your clinician.
Free, no accountRead your blood testGot a CBC and a vitamin D result? Read every line of your report, free.Read my results
LL-37 vs BPC-157 and other immune and repair peptides
| Peptide | What it is | Best human evidence | FDA-approved in the US? |
|---|---|---|---|
| LL-37 | The body's own germ-fighting peptide | Two topical leg-ulcer trials; the larger was negative | No |
| BPC-157 | Synthetic fragment of a stomach protein | No published controlled trials | No |
| Thymosin alpha-1 | Immune peptide from the thymus | Clinical trials in hepatitis B; approved in some other countries | No |
| GHK-Cu | Copper-binding peptide found in blood | Small cosmetic skin studies, topical | No |
| KPV | Three-amino-acid fragment of an anti-inflammatory hormone | Preclinical only | No |
Each of these sits in the same research-peptide market as LL-37, and none has the human trial record of an approved drug. Humanin is another peptide the body makes that is sold with claims well ahead of its human data.
Related research peptides
Citations
- Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J, 2005.
- Liu PT et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science, 2006.
- Martineau AR et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ, 2017.
- Mahlapuu M et al. Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: a multicentric prospective randomized placebo-controlled clinical trial. Wound Repair Regen, 2021 (trial results, EU Clinical Trials Register 2018-000536-10).
- Lande R et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature, 2007.
- Yamasaki K et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med, 2007.
- US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2), content current as of 22 April 2026.
- RAPS. FDA considers adding a dozen peptides to its bulk drug compounding list, 16 April 2026.
Educational context only, not medical advice or a diagnosis. Always discuss your results with a clinician.







